EUVIMEDEUVIMED entdecken
Crossref

Crooke Cell Adenoma: Is Its Aggressiveness Overestimated? Evidence From a Single‐Centre Experience

Ilkin Muradov iD, Serdar Sahin iD, Sumeyye Akpinar iD, Ali Tunc iD, Banu Betul Kocaman iD, Lala Soltanova iD, Cansu Turker Saricoban iD, Nil Comunoglu iD, Necmettin Tanriover iD, Nurperi Gazioglu iD, Hande Mefkure Ozkaya iD, Pinar Kadioglu iD

Clinical Endocrinology · 2026

DOI: 10.1111/cen.70121 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Endocrinology, 2026. Verfasst von Ilkin Muradov und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Endocrinology and Metabolism, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, …. Hauptthemen laut MEDLINE: Adenoma, Pituitary Neoplasms, ACTH-Secreting Pituitary Adenoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Crooke cell adenomas (CCAs) are considered rare and potentially aggressive variants of corticotroph adenomas. However, data on their clinical behaviour remain limited. This study aimed to compare the clinical, biochemical, radiological, and surgical outcomes of patients with CCAs and non‐CCA Cushing's disease (CD). Material and Methods We retrospectively analyzed patients diagnosed with CD at our tertiary Pituitary Centre. Clinical presentation, baseline biochemical characteristics, tumour size, Ki‐67 index, remission rates, recurrence, and presence of residual tumour on follow‐up MRI were compared between CCA and non‐CCA groups.

Results

At baseline, patients with CCAs ( n = 21) and non‐CCAs ( n = 60) demonstrated comparable biochemical profiles, except for ACTH levels, which were higher in the CCA group compared with the non‐CCA group ( p = 0.007). Remission and recurrence rates at 3, 6, and 12 months did not differ significantly between the two groups ( p > 0.05 for all). However, CCAs tended to present with larger tumour sizes and higher Ki‐67 proliferation indices than non‐CCAs ( p = 0.055 and p = 0.05, respectively). Moreover, residual pituitary lesions were more frequently detected on follow‐up MRI among patients with CCA ( p = 0.005).

Conclusion

Our findings suggest that CCAs may not be as aggressive as previously assumed with respect to biochemical remission and recurrence rates. Nonetheless, their larger tumour size, higher proliferative index, and increased likelihood of residual disease underscore the importance of careful long‐term follow‐up. Further multicenter studies are warranted to better characterize the clinical course of CCAs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenomaPituitary NeoplasmsACTH-Secreting Pituitary AdenomaHumansFemaleMaleRetrospective StudiesMiddle AgedAdultPituitary ACTH HypersecretionKi-67 AntigenMagnetic Resonance ImagingNeoplasm Recurrence, LocalAdrenocorticotropic Hormone

Stichwörter der Autor:innen

Crooke cell adenomaCushing′s diseaseadrenocorticotropic hormonepituitary adenoma

Substanzen

Ki-67 AntigenAdrenocorticotropic Hormone

Autor:innen und Institutionen

  • Department of Internal Medicine, Division of Endocrinology and Metabolism, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey.
  • Pituitary Center, Istanbul University-Cerrahpaşa, Istanbul, Turkey.
  • Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey.
  • Department of Pathology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey.
  • Department of Neurosurgery, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey.
  • Department of Neurosurgery, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa (retiree), Istanbul, Turkey.

ORCID-Profile: Ilkin Muradov, Serdar Sahin, Sumeyye Akpinar, Ali Tunc, Banu Betul Kocaman, Lala Soltanova, Cansu Turker Saricoban, Nil Comunoglu, Necmettin Tanriover, Nurperi Gazioglu, Hande Mefkure Ozkaya, Pinar Kadioglu

Zitieren

APA

Muradov, I., Sahin, S., Akpinar, S., Tunc, A., Kocaman, B. B., Soltanova, L., Saricoban, C. T., Comunoglu, N., Tanriover, N., Gazioglu, N., Ozkaya, H. M., & Kadioglu, P. (2026). Crooke Cell Adenoma: Is Its Aggressiveness Overestimated? Evidence From a Single‐Centre Experience. Clinical Endocrinology. https://doi.org/10.1111/cen.70121

Vancouver

Muradov I, Sahin S, Akpinar S, Tunc A, Kocaman BB, Soltanova L, et al. Crooke Cell Adenoma: Is Its Aggressiveness Overestimated? Evidence From a Single‐Centre Experience. Clinical Endocrinology. 2026. doi:10.1111/cen.70121

BibTeX
@article{Muradov2026,
  author = {Muradov, Ilkin and Sahin, Serdar and Akpinar, Sumeyye and Tunc, Ali and Kocaman, Banu Betul and Soltanova, Lala and Saricoban, Cansu Turker and Comunoglu, Nil and Tanriover, Necmettin and Gazioglu, Nurperi and Ozkaya, Hande Mefkure and Kadioglu, Pinar},
  title = {Crooke Cell Adenoma: Is Its Aggressiveness Overestimated? Evidence From a Single‐Centre Experience},
  journal = {Clinical Endocrinology},
  year = {2026},
  doi = {10.1111/cen.70121}
}
Kostenlos starten →